Drugs / APVAC2 vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02149225 | Oct 2014 → Jun 2018 | glioblastoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APVAC2 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02149225 ↗ |
| Modality | Vaccine | “APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the...” NCT02149225 ↗ |